Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection

Pharmacogenomics. 2015;16(10):1179-88. doi: 10.2217/pgs.15.65. Epub 2015 Aug 7.

Abstract

Chronic HCV infection comprises a broad spectrum of liver disease, ranging from no or minimal activity to active hepatitis that in time may progress to severe liver fibrosis, cirrhosis and hepatocellular carcinoma if left untreated. This review describes the impact of genetic variants of interleukin 28B (IL28B; also known as interferon-lambda 3), inosine triphosphate pyrophosphatase (ITPA) and patatin-like phospholipase domain-containing 3 (PNPLA3) on therapeutic outcome and liver disease severity in HCV-infected patients.

Keywords: HCV; IL28B; ITPA; ITPase; PNPLA3; genetic variant; histology; inosine triphosphate pyrophosphatase; interferon-λ; natural history; therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Disease Progression
  • Genetic Variation / genetics*
  • Hepacivirus / pathogenicity
  • Hepatitis C / genetics*
  • Hepatitis C / virology
  • Humans
  • Interferons
  • Interleukins / genetics*
  • Lipase / genetics*
  • Membrane Proteins / genetics*
  • Pyrophosphatases / genetics*

Substances

  • IFNL3 protein, human
  • Interleukins
  • Membrane Proteins
  • Interferons
  • Lipase
  • adiponutrin, human
  • Pyrophosphatases
  • ITPA protein, human